首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1532591

溶瘤病毒治療市場 - 病毒類型（基因工程溶瘤、溶瘤野生型）、應用（實體瘤、黑色素瘤）、最終用戶（醫院、專科診所、癌症研究機構） - 全球預測（2024 - 2032）

Oncolytic Virotherapy Market - Virus Type (Genetically Engineered Oncolytic, Oncolytic Wild-type), Application (Solid Tumors, Melanoma), End user (Hospitals, Specialty Clinics, Cancer Research Institutes) - Global Forecast (2024 - 2032)

出版日期: 2024年05月27日 | 出版商:

Global Market Insights Inc. | 英文 125 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球溶瘤病毒治療市場在 2024 年至 2032 年期間將成長 26.9%，這歸因於癌症研究投資的不斷增加，加速了創新療法的發現和發展。這些投資支持廣泛的臨床前和臨床研究，以最佳化溶瘤病毒的功效和安全性，促進標靶癌症治療的突破。增加的資金也支持聯合療法的開發，將溶瘤病毒療法與免疫療法等其他方式結合，以改善患者的治療效果。此外，研發的增加促進了生物技術公司、研究機構和製藥公司之間的合作，推動有效溶瘤病毒治療解決方案的商業化，並將其擴展到更廣泛的患者群體。

舉例來說，2023 年 9 月，美國聯邦政府宣布計劃投資近 1.15 億美元用於三個大學項目，旨在發現檢測和對抗癌症的新方法。作為拜登政府癌症登月計畫的一部分，這些計畫透過與衛生高級研究計畫局 (ARPA-H) 達成的協議獲得資助。這些研究中心將由密蘇里大學、萊斯大學和喬治亞理工學院領導。 ARPA-H 在癌症研究領域處於領先地位，支持政府在 25 年內將癌症死亡率降低一半的宏偉目標。

整個溶瘤病毒療法市場根據病毒類型、應用、最終用途和地區進行分類。

溶瘤野生型病毒部分將在 2024 年至 2032 年期間取得顯著進展。使用水泡性口炎病毒、新城疫病毒和呼腸孤病毒等野生型病毒的溶瘤病毒療法正受到關注，因為它們具有選擇性感染和破壞癌細胞同時不傷害健康組織的自然能力。這些病毒可以有效引發針對腫瘤的免疫反應，並增強人體的自然防禦能力。它們固有的溶瘤特性與基因工程的進步一致，使研究人員能夠提高其功效和安全性。因此，這些溶瘤野生型病毒正在成為開發創新癌症療法的有希望的候選者，推動了對該領域的巨大興趣和投資。

到 2032 年，在溶瘤病毒學解決傳統治療限制的潛力的推動下，黑色素瘤細分市場將佔據相當大的溶瘤病毒學市場。溶瘤病毒療法提供了一種有針對性的方法，特別是感染和殺死黑色素瘤細胞，同時保護健康組織。它能夠誘導針對腫瘤的強大免疫反應，從而提高整體治療效果。此外，溶瘤病毒工程的最新進展提高了安全性和有效性，使其成為抗藥性或晚期黑色素瘤患者的一個有前途的選擇。這種創新療法符合腫瘤學中對更有效、個人化治療策略的需求，促進了其在黑色素瘤護理中的採用。

由於對創新癌症治療的大力關注以及對研發的大量投資，歐洲溶瘤病毒學市場正在蓬勃發展。歐洲國家正積極支持溶瘤病毒療法的臨床試驗和監管途徑，為市場成長創造有利的環境。此外，生物技術公司、研究機構和醫療保健提供者之間的合作不斷增加，以及對標靶癌症治療的需求不斷成長，推動了溶瘤病毒學解決方案在整個地區的擴展。

產業生態系統分析
產業影響力
- 成長動力
  - 癌症發生率上升
  - 越來越多人批准溶瘤療法治療罕見的癌症
  - 增加開發新溶瘤病毒療法的投資
  - 越來越關注聯合療法
- 產業陷阱與挑戰
  - 與臨床級溶瘤病毒放大相關的問題
  - 臨床研究需要高額投資
成長潛力分析
未來市場趨勢
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按病毒類型，2021 - 2032 年

主要趨勢
基因工程溶瘤病毒
- 腺病毒
- 單純皰疹病毒
- 牛痘病毒
溶瘤野生型病毒
- 呼腸孤病毒
- 水泡性口炎病毒
- 新城疫病毒

第 6 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
實體腫瘤
- 乳癌
- 攝護腺癌
- 肺癌
- 膠質母細胞瘤
黑色素瘤
- 白血病
- 淋巴瘤
- 骨髓瘤
- 血液系統惡性腫瘤

第 7 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

主要趨勢
醫院
專科診所
癌症研究機構

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Amgen Inc.
BioVex, Inc.
Circio Holding ASA
Daiichi Sankyo Company
DNAtrix
Lokon Pharma AB
Medigene AG
Oncolytics Biotech Inc.
PsiOxus Therapeutics
Shanghai Sunway Biotech Co., Ltd.
SillaJen, Inc.
Sorrento Therapeutics
Theriva Biologics
Transgene SA
Virogin Biotech

簡介目錄

Product Code: 9645

Global Oncolytic Virotherapy Market will expand at 26.9% throughout 2024-2032, attributed to growing investments in cancer research accelerating the discovery and development of innovative treatments. These investments enable extensive preclinical and clinical studies to optimize the efficacy and safety of oncolytic viruses, fostering breakthroughs in targeted cancer therapy. Enhanced funding also supports the development of combination therapies, integrating oncolytic virotherapy with other modalities like immunotherapy to improve patient outcomes. Additionally, increased R&D facilitates collaboration between biotech companies, research institutions, and pharmaceutical firms, driving the commercialization of effective oncolytic virotherapy solutions and expanding their availability to a broader patient population.

Citing an instance, in September 2023, the U.S. federal government announced plans to invest nearly $115 million in three university-based projects aimed at discovering new methods to detect and combat cancer. These projects are funded through agreements with the Advanced Research Projects Agency for Health (ARPA-H) as part of the Biden administration's Cancer Moonshot initiative. The research centers will be led by the University of Missouri, Rice University, and the Georgia Institute of Technology. ARPA-H is leading the way in pioneering cancer research, supporting the Administration's ambitious goal to halve the cancer death rate within 25 years.

The overall oncolytic virotherapy market is categorized based on virus type, application, end use, and region.

The oncolytic wild-type viruses segment will amass significant gains over 2024-2032. Oncolytic virotherapy using wild-type viruses like vesicular stomatitis virus, Newcastle disease virus, and reovirus is gaining traction due to their natural ability to selectively infect and destroy cancer cells while sparing healthy tissue. These viruses can effectively trigger immune responses against tumors, enhancing the body's natural defenses. Their inherent oncolytic properties, in line with advancements in genetic engineering, enable researchers to improve their efficacy and safety profiles. As a result, these oncolytic wild-type viruses are becoming promising candidates in the development of innovative cancer therapies, driving significant interest and investment in the field.

The Melanoma segment will capture a decent oncolytic virology market share by 2032, driven by the potential of oncolytic virology to address the limitations of traditional treatments. Oncolytic virotherapy offers a targeted approach, specifically infecting and killing melanoma cells while sparing healthy tissue. Its ability to induce a robust immune response against tumors enhances overall treatment efficacy. Additionally, recent advancements in oncolytic virus engineering improve safety and effectiveness, making it a promising option for patients with resistant or advanced melanoma. This innovative therapy aligns with the need for more effective, personalized treatment strategies in oncology, boosting its adoption in melanoma care.

Europe oncolytic virology market is thriving due to a robust focus on innovative cancer treatments and substantial investment in research and development. European countries are actively supporting clinical trials and regulatory pathways for oncolytic virotherapy, fostering a favorable environment for market growth. Additionally, increasing collaborations between biotech firms, research institutions, and healthcare providers, along with rising demand for targeted cancer therapies, drive the expansion of oncolytic virology solutions across the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of cancer
  - 3.2.1.2 Growing approvals for oncolytic therapy for treating rare cancers
  - 3.2.1.3 Increasing investments for developing new oncolytic virotherapies
  - 3.2.1.4 Growing focus towards combination therapies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Issues related to scaling-up of clinical-grade oncolytic viruses
  - 3.2.2.2 Requirement for high investments in clinical research
3.3 Growth potential analysis
3.4 Future market trends
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Virus Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Genetically engineered oncolytic viruses
- 5.2.1 Adenovirus
- 5.2.2 Herpes simplex virus
- 5.2.3 Vaccinia virus
5.3 Oncolytic wild-type viruses
- 5.3.1 Reovirus
- 5.3.2 Vesicular stomatitis virus
- 5.3.3 Newcastle disease virus

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Solid tumors
- 6.2.1 Breast cancer
- 6.2.2 Prostate cancer
- 6.2.3 Lung cancer
- 6.2.4 Glioblastoma
6.3 Melanoma
- 6.3.1 Leukemia
- 6.3.2 Lymphoma
- 6.3.3 Myeloma
- 6.3.4 Hematological malignancies

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Cancer research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa